血清胸苷激酶1检测对消化道恶性肿瘤诊断及疗效评估的意义  

Evaluation of the significance of serum thymidine kinase 1 detection in the diagnosis and curative effect of gastrointestinal malignant tumors

作　　者：沈菁[1] 陈雯[1] 徐如梅[1] 张建钫[1] 江华[1] 

机构地区：[1]福建省立医院检验科,福建福州350001

出　　处：《实验与检验医学》2011年第5期531-533,共3页Experimental and Laboratory Medicine

摘　　要：目的探讨血清胸苷激酶1(sTK1)在消化道恶性肿瘤诊断及临床治疗效果评估的意义。方法应用免疫印迹-增强化学发光法检测100例治疗前后的消化道恶性肿瘤患者、50例消化道良性疾病者及60例健康对照者的sTK1水平。结果恶性肿瘤组治疗前sTK1水平显著高于消化道良性疾病和健康体检者(P<0.01),食道癌、胃癌和结直肠癌三组间sTKI水平无显著性差别(P>0.05),各组治疗前、后的sTKl水平间有显著性差别(P<0.01),消化道良性疾病和健康体检者sTKI水平无显著性差别(P>0.05)。结论血清胸苷激酶1检测在消化道恶性肿瘤的诊断、疗效监测及预后判断上具有一定的应用价值。Objective To investigate the diagnostic significance of serum thymidine kinase 1（sTK1） detection,and evaluate the curative effect for gastrointestinal malignant tumors.Methods Western blot-enhanced chemiluminescence assay was used to detect sTK1 levels from 100 patients with gastrointestinal malignant tumors before and after treatment,50 cases with benign gastrointestinal disieases and 60 healthy people.Results The mean value of sTKl in patients group before treatment was significantly higher than that in gastrointestinal benign diseases and the healthy control（P0.01）.There was no significant difference of sTKl levels among esophagus,gastric and colorectal carcinoma（P0.05）,sTKl levels showed significantly statistical difference between before-treatment and after-treatment for these three groups（P0.01）.There was no significant difference of sTKl levels between benign gastrointestinal group and the healthy controls（P0.05）.Conclusion sTK1 may have a certain value in the diagnosis,curative effect evaluation,prognosis prediction for gastrointestinal malignant tumors.

关 键 词：胸苷激酶 免疫印迹-增强化学发光法 消化道恶性肿瘤 

分 类 号：R446.62[医药卫生—诊断学] R735[医药卫生—临床医学]